|
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
HeartCheck™ Technologies to be used to identify people at risk for potentially life-threatening drug side effects
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today announced it has entered into a partnership agreement with the Clinical Neuroendocrinology Laboratory at the University of Texas at Austin (UT-Austin). The agreement involves CardioComm Solutions supplying HeartCheck™ ECG recording devices and access to the Company's patent-pending SMART Monitoring ECG services to be used in screening research subjects for the presence or absence of medication induced cardiac abnormalities.
Through the partnership, the UT-Austin research team will purchase HeartCheck™ devices and access to the SMART Monitoring ECG service. CardioComm Solutions will also provide enhanced training and support to the research staff and consultation as requested on protocol methodologies. All projects will involve collection of ECG data from research subjects by the UT-Austin research team using the HeartCheck™ ECG monitor. The resulting ECG files will be imported into CardioComm Solutions' GEMS™ Home file management software. Selected ECGs will then be transferred into the CardioComm Solutions cloud-based SMART Monitoring ECG service where the Company will provide ECG interpretation services and ECG over-read by a cardiac electrophysiologist.
"The CardioComm Solutions' ECG technologies are a critical part of our research protocols. The web-based ECG services will allow ECGs that are produced by HeartCheck™ ECG devices to be securely uploaded to CardioComm Solutions' ECG core lab services," stated Robert Josephs, who has appointments in the Department of Psychology, Institute for Neuroscience, and Institute for Mental Health Research at UT-Austin. "We expect our relationship with CardioComm Solutions to play a continuing and key role in our ongoing drug trials, which are designed to shed new light on the biologic processes underlying anxiety, depression, post-traumatic stress disorder and psychopathy. Combining their FDA cleared ECG management technology and service with our experience in the performance of clinical research studies will increase the likelihood that our projects will expand into large, multi-site NIH peer-reviewed research projects."
"Our partnership with the Clinical Neuroendocrinology Laboratory at UT-Austin fits our corporate goal for continued support of research and expansion of the use of our ECG monitoring technologies. Support of such research studies, with in-kind contributions, furthers our intention to develop long-term and mutually-beneficial relationships with universities, hospitals and pharmaceutical companies. These relationships will also have the added benefit of allowing CardioComm Solutions to participate in the publication of peer-reviewed studies, which will serve to: a) further validate our systems in clinical and research applications, and b) help position CardioComm Solutions' devices as the standard ECG screening technology for use in large, multi-centre, peer-reviewed studies. These proposed expansions will lead to the generation of new revenue streams from the sales of devices and ECG reading, Software as a Service (SaaS) use," reported Etienne Grima, Chief Executive Officer of CardioComm Solutions.
More information regarding the use of the HeartCheck™ products and SMART Monitoring ECG service in clinical, commercial and research use can be found at www.theheartcheck.com.
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
forward-looking information.
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Obligations).
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
